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Abstract: An ellagic acid (EA)–zinc layered hydroxide (ZLH) nanohybrid (EAN) was   synthesized 
under a nonaqueous environment using EA and zinc oxide (ZnO) as the precursors. Powder X-ray 
diffraction showed that the basal spacing of the nanohybrid was 10.4 Å,   resulting in the spatial 
orientation of EA molecules between the interlayers of 22.5° from z-axis with two negative charges 
at 8,8′ position of the molecules pointed toward the ZLH interlayers. FTIR study showed that the 
intercalated EA spectral feature is generally similar to that of EA, but with bands slightly shifted. 
This indicates that some chemical bonding of EA presence between the nanohybrid interlayers was 
slightly changed, due to the formation of host–guest interaction. The nanohybrid is of mesopores 
type with 58.8% drug loading and enhanced thermal stability. The release of the drug active, EA 
from the nanohybrid was found to be sustained and therefore has good potential to be used as 
a drug controlled-release formulation. In vitro bioassay study showed that the EAN has a mild 
effect on the hepatocytes cells, similar to its counterpart, free EA.
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Introduction
Systemic drug delivery leads to distribution of the drug throughout the body through 
blood circulation, which can lead to drug concentration accumulation in unwanted 
parts of the body that causes severe side effects. Additionally, conventional drug 
administration methods do not provide satisfactory pharmacokinetic profiles because 
the drug concentration rapidly falls below the desired levels.1 Cancer chemotherapy 
is the treatment of cancer cells with an antineoplastic drug. The main property of 
cancer cells is rapid division. Chemotherapy acts by killing cells that divide rapidly, 
which means it also harms cells that divide rapidly under normal circumstances such 
as cells in the bone marrow, digestive tract, and hair follicles, producing side effects 
such as myelosuppression,2 mucosities,3 and alopecia.4 To overcome these side effects, 
researchers are now searching for efficient and safe transport carriers, which prolong 
exposure time to drugs and target cancerous cells without targeting healthy cells.
In the past few decades, many carriers have been developed, and generally can be 
classified into four major groups: viral carriers, recombinant proteins, organic cationic 
compounds, and inorganic nanoparticles.5,6
Recently, inorganic nanoparticles have attracted considerable attention due to 
their versatile features, such as wide availability, good biocompatibility, rich sur-
face functionality, potential capability of target delivery, and controlled release 
of the drug from the inorganic nanoparticles.7–9 Calcium phosphate, gold, carbon 
nanotubes, silicon oxide, iron oxide and layered double hydroxides are examples International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of inorganic   nanoparticles, which have intensively investi-
gated in different studies by different groups.10–15 Layered 
double hydroxides (LDH) are materials with a number of 
advantages for drug delivery. Among these are their ease 
of laboratory preparation with a controlled particle size,16 
and the drugs can be easily loaded into the interlayers 
space by ion exchange,   comparing with other nanoparticles 
which need further modification such as surface functional 
modification.17,18 Layered double hydroxides have a high zeta 
potential, 20–30 mV , which provides a strong driving force 
on to the surface of a cell. LDH are degraded in an acidic 
environment to form M2+, M3+, and X- ions which leads the 
drug actives leaving the cell through the ion-tunnels, whereas 
the others inorganic nanoparticles accumulate in the cells 
because of their low solubility in the cells. Low cytotoxicity 
is another virtue of LDH. Hussein et al reported that there 
is no toxic effect of Zn–Al LDH at low concentration on 
Chinese hamster ovary cells.19
LDH, also known as hydrotalcite-like compounds, are 
formed by layered units in which metal cations are octahe-
drally coordinated with hydroxyl groups, as in the brucite 
(Mg(OH)2) structure. The isomorphic substitution of divalent 
cations by trivalent cations leaves a residual positive charge 
that is stabilized by inter layer anions. The general formula 
for hydrotalcite is  MM (OH) (A ) . HO , / 1
23
22 −
++ − 



+
xx xm
X
n
m  
where M2+ is divalent cations, M3+ is trivalent cations and 
Am- is exchangeable anion with charge (m-).20 Similar to 
LDH, zinc layered hydroxide (ZLH) is a compound whose 
structure derived from brucite. One quarter of the octahe-
dral coordinated zinc cations are displaced from the main 
layer to tetrahedral sites located above and below each 
empty octahedron and can be represented by the general 
formula  MO HA
2+
−
− () 2 2 x
m
xm n () . HO / , where M2+ is the 
Zn2+ and Am- is counter ions with (m-) charge.21
Because of ZLH anionic exchange capacity, many active 
compounds can be intercalated into ZLH interlayers. These 
include the anticarcinogenic agent gallic acid,22 linoleic 
acid,23 sunscreen materials such as 2-amino benzoic acid 
and 4-amino benzoic acid,24 nucleoside monophosphate, 
DNA,25 and pharmaceutical, cosmeceutical, and nutraceuti-
cal compounds.26
Various methods have been adopted for preparation 
of ZLH and its nanohybrids, namely hydrolysis of salt 
and oxides,27 urea hydrolysis,28 precipitation with alkaline 
solutions,29 and solid state reaction.30 Direct reaction of zinc 
oxide (ZnO) is simple and easily used either for aqueous 
or nonaqueous systems. Such a method is economic and 
environmentally friendly as fewer steps and chemicals are 
involved.
Ellagic acid (EA) is an antioxidant, which is a family 
of drugs much used for cancer treatment. Intense research 
has been conducted to investigate the effect of EA on the 
cancer cell as well as its delivery.31–34 Lately, many articles 
have described the preparation of ZLH as a starting mate-
rial followed by intercalation of the anion. However, to the 
best of our knowledge, little work has been published on 
the use of ZnO as a starting material to intercalate drug 
actives.35,36 Therefore, the main objective of this work was 
to explore the potential use of ZnO as a starting material 
for the intercalation of EA for the formation of a new 
EA–ZLH nanohybrid (EAN). The resulting nanohybrid 
was then used as a   controlled release formulation of drug 
active EA. A cytotoxicity study of nanohybrids was also 
carried out.
Experimental
Materials
All chemicals used in this study were of analytical grade 
and used without any further purification. Hydrated EA 
(97% purity) was purchased from Sigma-Aldrich (St Louis, 
MO) and pure commercial ZnO of ACS reagent was used, 
purchased from Fisher Scientific (Waltham, MA). Dimethyl 
sulfoxide (DMSO) was purchased from Ajax Finechem 
(Sydney, Australia) with 0.1% water content used as 
solvent.
Method
Typically, the appropriate amount of hydrated EA (0.0013 mol) 
was dissolved in DMSO followed by 10   minutes stirring and 
heating for 40°C. The ZnO (0.2 g) was mixed with the solu-
tion of EA and stirred at 70°C for 8 hours. After filtration and 
washing with deionized water three times, the sample was 
dried in an oven at 60°C for 12 hours. The resulting material 
was then powdered and stored in a sample bottle for further 
use and characterization.
characterization
Powder X-ray diffraction (PXRD) patterns were recorded at 
a range of 2–60° on a Shimadzu diffractometer, XRD-6000 
(Tokyo, Japan) using CuKα radiation at 40 kV and 30 mA. 
Fourier transform infra-red (FTIR) spectra of the materials 
were recorded over the range 400–4000 cm-1 on a Perkin-
Elmer 1752X spectrophotometer (Waltham, MA) using a 
KBr disc method. For carbon, hydrogen, nitrogen and sulfur International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(CHNS) analyses, a CHNS-932 model of LECO instru-
ment (St Joseph, MI) was used. Thermogravimetric and 
differential thermogravimetric analyses (TGA-DTG) were 
carried out using a Mettler Toledo instrument (  Greifensee, 
  Switzerland). Surface characterization of the material was 
carried out using a nitrogen gas adsorption–desorption 
technique at 77 K using a Micromeritics ASAP 2000 
(Norcross, GA). The surface morphology of the samples 
was observed by a scanning electron microscope (SEM), 
using JOEL JSM-6400 (Tokyo, Japan). UV-Vis spectra for 
optical properties and controlled-release study were accom-
plished using a Perkin Elmer UV-Vis Spectrophotometer, 
Lambda 35.
controlled-release study
Drug release profiles were determined at room temperature 
by using 0.1 M Na2CO3
37 and Na3PO4
38 solutions. Both anions 
CO PO 3
2
4
3 −− ,  are commonly used for preliminary study of 
drug release, to observe the controlled-release     property of 
the intercalated drug actives. This was also conducted to 
study the effect of different negative species  CO PO 3
2
4
3 −− ,  
on the rate of release. The UV-Vis spectrum of DMSO 
and EA dissolved in DMSO shows intense absorbance at 
224.0 and 257.5 nm, respectively. Therefore, DMSO is an 
interference-free solvent. The EA released was measured 
at a   predetermined time by UV-Vis spectrophotometer at 
257.5 nm.39 The EA release kinetics was fitted to four models, 
as shown in Table 2.40–43
In vitro bioassay
The cytotoxicity effect of ZnO, EA, and EAN against 
healthy rat hepatocytes was examined by a cell viability 
test.   Hepatocytes from normal healthy Sprague Dawley 
rats (n = 4) were isolated by a two-step collagenase 
  perfusion technique.44–46 Viability of freshly isolated rat 
  hepatocytes was determined by trypan blue exclusion. 
After   isolation, hepatocytes suspensions were incubated 
at a   density of 1 × 106 viable cells/mL in Leibovitz 
  Glutamax I (L-15 incomplete) medium. About 25 µg/mL 
EA, EAN, and ZnO were added to DMSO (final DMSO 
  concentration of 1.0% v/v). Control hepatocytes suspen-
sions were incubated with an equivalent amount of DMSO. 
The flasks were sealed in 95% O2/5% CO2 and placed in 
a shaking water bath at 37°C. Samples were taken from 
these flasks at time points of 0, 0.5, 1, 3, and 6 hours for 
a viability test.
Viable cells were determined by lactate dehydroge-
nase activity in medium and in the lysed cells at each time 
point. The activity was assessed spectrophotometrically as 
described by Marshall and Caldwell.45
Results and discussion
PXrD and eA orientation between ZLH 
interlayers
Figures 1A, B, and C show PXRD patterns of ZnO, EAN, 
and EA, respectively. For ZnO sample, the five intense 
  reflections shown in Figure 1A at 30–60° correspond to 
Table 2 Correlation coefficient, rate constant, and half time obtained by fitting the data of the release of EA from EAN into 0.1 M 
Na2cO3 and 0.1 M Na3PO4; the equation of kinetic models used for the fitting is also indicated
Aqueous   
solution
Saturated  
release %
r2 Rate constant (k)   
pseudo-second  
order (g/mg∙h)
t1/2 pseudo-second   
order (h) Zeroth-order First-order Pseudo-second   
order
Parabolic   
diffusion
Na2cO3 69% 0.6683 0.7635 0.9985 0.7997 0.0044 3.03
Na3PO4 94% 0.3963 0.7381 0.9996 0.5926 0.0175 0.61
Kinetic  
equation
Zeroth-order First-order Pseudo-second order Parabolic diffusion
Mt - Mo = -kot log (Mt/Mo ) = -k1t t/qt = 1/h + t/qe (1 - Mt/Mo)/t = Kdt-0.5 + a
Notes: Mo is the eA content remained in the ZLH at release time o, Mt is the eA content remained in the ZLH at release time t, qe is the equilibrium release amount and qt 
is the release amount at time t, h = k2qe
2, k the corresponding release rate constant, a is constant whose chemical significance is not clearly resolved.43
Abbreviations: eA, ellagic acid; ZLH, zinc layered hydroxide.
Table 1 Physicochemical properties of ZnO and ZLH-nanohybrid, eAN
Compounds C (%) H (%) Zn (%w/w) aAnion  
(%w/w)
BET surface  
area (m2/g)
BJH pore  
diameter (Å)
BJH pore  
volume (cm3/g)
ZnO – – (80.3) – 6.4 111 0.010
eAN 32.7 2.6 29.3 58.8 3.6 170 0.007
Notes: aestimated from cHNs analysis; value in the parentheses is the theoretical value.
Abbreviations: BJH, Barret–Joyner–Helenda; BeT, Brunauer, emmett and Teller; c, carbon; H, hydrogen; eAN, ellagic acid nanohybrid; ZnO, zinc oxide; ZLH, zinc layered 
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diffractions due to 100, 002, 101, 102, and 110 planes. 
Figure 1B shows the PXRD pattern of EAN synthesized by 
direct reaction between 0.025 M hydrated EA with ZnO. As   
reported in the literature, the zinc hydroxide nitrate has sharp 
reflection at 9.7 Å due to the 200 plane of the monoclinic 
structure.47,48 After the intercalation of the anions, the basal 
distance increased more than 9.7 Å due to the   displacement 
of exchangeable nitrate anions and depending on the 
  dimensions and the spatial orientation of the guest anion 
that is intercalated into the ZLH inorganic interlayers.48 As 
shown in the Figure 1B, the formation of the EAN can be 
  confirmed by the observation of two new diffraction pat-
terns at d = 10.4 Å and 5.2 Å, which is due to 003 and 006 
reflection, respectively. Total disappearance of the intense 
peaks of ZnO phase indicated that the sample EAN is pure 
phase and the ZnO was completely converted to ZLH.36
The formation of EAN is believed to occur through a 
dissociation–deposition mechanism36,49 which takes place in 
the nonaqueous solution of hydrated EA. The mechanism is 
composed of three steps:
1.  Hydrolysis of ZnO in water into hydrated EA to form 
Zn(OH)2 on the surface of the solid particles
      ZnO + H2O → Zn(OH)2
2.  Formation Zn2+ species by dissociation of Zn(OH)2
      Zn(OH)2 → Zn2+ + 2OH-
3.  In addition, reaction between Zn2+ ions formed with 
hydroxyls, H2O and EA anions in the solution generate 
the layered nanohybrid compound,
  Zn2+ + 2OH-+ EA-+ H2O  
  → Zn2+ (OH)2-x (EAm-)x/m ⋅ nH2O
The EA has the molecular structure of a planar phenolic 
lactone that is doubly deprotonated at positions 8 and/or 8′ 
when the pH is more than 5.6.50 Figure 2A shows the three-
dimensional molecular size of EA obtained using Chemoffice 
software (Cambridge, MA).
Figure 2B shows that the thickness of the ZLH is 
4.8 Å51 and d-spacing of the ZLH samples intercalated by 
EA from XRD spectrum is 10.4 Å. Therefore, the gallery 
height avialable to be occupied is 5.6 Å, which is smaller 
than 12.4 Å or 9.8 Å, the dimension of EA. In addition, the 
thickness of two molecules of EA is about 5.8 Å, which is   
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bigger than the gallery height. This means that the EA has to 
be oriented between the interlayers as a monolayer and the 
spatial orientation of the molecule is with an angle of 22.5° 
from z-axis as shown in Figure 2B.
FTIr spectroscopy
The FTIR spectra of the EAN nanohybrid and EA are 
given in Figure 3. The FTIR spectrum of EA shows 
an absorption band at 3557 cm-1, attributed to the 
stretching mode of OH groups in the phenol at 7,7′, 
8 and 8′ positions (  Figure 2A)52 and broad absorption 
bands at 3500–2750 cm-1 can be attributed to stretching 
of C–H aromatic ring24 and hydrogen bond between EA 
molecules.50 A band at 1700 cm-1 is due to stretching of 
C=O52,53 and bands at 1620–1511 cm-1 are due to aromatic 
rings. A band at 1196 and 1058 cm-1 is due to ester linkage 
of C–O stretching34,52 and another band at 758 cm-1 is due 
to C–H aromatic stretching.
FTIR spectrum of EAN (Figure 3B) shows character-
istic bands of pure EA together with other band of ZLH. 
This indicates that the EA has been intercalated into the 
interlayer galleries of ZLH. Band for C=O, C–O ester 
linkage and C–H aromatic are slightly shifted in position 
to 1689, 1064, 750 cm-1, respectively, due to the i  nteraction 
between EA and the host interlayers as a result of the 
intercalation process. A broad absorption band observed at 
2500–3600 cm-1 is attributed to OH stretching due to the 
presence of hydroxyl group within the ZLH and phenolic 
hydroxide at position 7,7′.50 A band at 1577 cm-1 can be 
attributed to C=C stretching vibration of aromatic,52 and 
a band for ν(C–O) can be observed at 1107 cm-1 and ν 
(Zn–O) absorption bands at 472 cm-1. This indicates that 
the EA is coordinated to the inorganic layers by the nega-
tively charged oxygen atoms at positions 8 and 8′.50,54 The 
successful intercalation of EA into ZLH can be supported 
by CHNS analysis as shown in Table 1. EAN shows 32.7% 
carbon (w/w) and 2.6% (w/w) hydrogen, resulted in load-
ing percentage of EA in the nanohybrid of about 58.8%. 
Elemental analysis using ICP/AES shows EAN contains 
29.3% Zn (w/w).
Thermal analysis
TGA-DTG thermogravimetric analysis obtained for EA and 
EAN is shown in Figure 4. The TGA-DTG thermograms 
of EA (Figure 4A) show the first step weight loss, which 
can be attributed to the removal of bonded water with 
hydrogen bond at temperature maxima of 112°C (8.2%). 
The onset of weight loss of EA occurs at 381°C with two 
steps weight loss at 463°C (39%) and 596°C (17.5%). 
Because of the intercalation, the shape of the TGA-DTG 
curves (Figure 4B) is changed. The first weight loss at 78°C 
in the DTA curve corresponding to the absorbed water. 
The absence of a band at 1600 cm-1 in the FTIR spectrum 
confirming the absence of water between the interlayers.55 
The onset of dehydroxylation of zinc hydroxide layers 
and decomposition of EA occurs at around 496°C, with 
a rapid weight loss occurring in the temperature range at 
496°C–819°C with two steps at 585°C (24%) and 714°C 
(25.2%). These temperatures are higher than the decom-
position temperature of pure EA. This result indicates that 
the inorganic layers of ZLH enhanced the thermal stability 
of EA, the organic moiety.
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surface properties
Nitrogen adsorption–desorption isotherm for ZnO and 
EAN are shown in Figure 5A, shows features which can be 
described as Type IV in IUPAC classification, indicating 
mesopores-type material.56 The adsorption of ZnO and EAN 
increased slowly at low pressure in the range of 0.0–0.8, 
followed by rapid adsorption of the absorbent at relative 
pressure of 0.8 and above. The desorption branch of the 
hysteresis loop for ZnO is much narrower compared to EAN, 
indicating different pore texture of the resulting materials. 
This is due to the formation of ZLH with a basal spacing of 
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10.4 Å as well as the formation of interstitial pores.57 As a 
result of nitrogen adsorption study, we obtained the Breuneur, 
Emmet, and Teller (BET) surface area of the materials as 
shown in Table 1. The intercalation of EA into ZLH for the 
formation of EAN resulting in the decrease of the surface 
area from 6.4 m2/g for ZnO to 3.6 m2/g for EAN. This is 
attributed to the increase in the particles size and decrease 
of the pore volume.
Barret-Joyner-Halenda (BJH) pore size distribution 
for ZnO and EAN are shown in Figure 5B. Both   materials 
show mesopores character, in agreement with the   adsorption International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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isotherm of Type IV. BJH pore size   distribution of ZnO 
(Figure 5B) shows different features to that of EAN, 
indicating that the pore texture was modified, which is in 
agreement with the formation of EAN with a basal spacing 
of 10.4 Å. The BJH pore diameter of ZnO is lower than that 
of EAN. The increase from 111 to 170 Å is as a result of the 
intercalation of EA into the interlayer of ZLH.
Surface morphology of the samples, studied by field emis-
sion SEM for ZnO and EAN are shown in Figure 6. ZnO reveals 
nonuniform granular structure without any specific shape, 
with various sizes and shapes (Figure 6A). This structure was 
transformed into rod-like agglomerates with nonuniform size 
and shapes as shown in Figures 6B–C, when the intercalation 
of EA into the interlayer of ZLH had taken place.
Optical properties
UV-Vis spectroscopy was used to investigate whether the 
intercalation of EA into the ZLH host resulted in changes in 
its optical properties. Figure 7A shows the UV-Vis spectra of 
pristine EA as well as EAN. It can be seen that pristine EA 
exhibits a strong absorption band at 350 nm with a shoulder 
at 370 nm, corresponding to the π → π* transition of EA. 
When EA was intercalated into ZLH interlayers, the 370 nm 
band was slightly increased in intensity, indicating doubly 
deprotonated EA between the interlayers.50 This verifies that 
the drug molecules are stabilized by electrostatic interaction 
with the positive charge of ZLH.
In order to estimate the energy band gap, the Kubelka–
Munk (K–M) equation (1) was adopted,58
A B C
Figure 6 FeseM image of ZnO (A) and eAN (B) and EAN at higher magnification (C).
Abbreviations: FeseM, field emission scanning electron microscope; EA, ellagic acid; EAN, ellagic acid nanohybrid.
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  (F ⋅ hν)2 = A(hν - Eg)  (1)
where F is the K–M, h is Bohr constant, Eg is the energy band 
gap in electron volt units.
It is clear from Eq. (1) that the band gap can be obtained 
by plotting (F ⋅ hν)2 against hν in electron volts. Using the 
data obtained from Figure 7B, the band gap energy, E (eV) 
was determined, which is 3.29, 2.55, and 2.95 eV for ZnO, 
EAN, and EA, respectively. The value of band gap for ZnO 
determined in this work is similar to a band gap energy for 
ZnO determined previously.59
release behavior of the eA
The release profiles of EA from EAN using 0.1 M Na2CO3 and 
0.1 M Na3PO4 separately and free EA are shown in   Figure 8. 
As can be seen from Figures 8C and D, the free EA released 
quickly into Na2CO3 and Na3PO4 solutions, the release being 
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Figure 9 Fitting of the data of EA released from the EAN into solution to the zeroth-, first-, pseudo-second-order kinetics, and parabolic diffusion for 0.1 M Na2cO3 (A, B, 
C, and D respectively) and Na3PO4 (E, F, G, and H, respectively).
Abbreviations: eA, ellagic acid; eAN, ellagic acid nanohybrid; ZnO, zinc oxide.
0
0
15
30
45
60
75
90
A
Zero order
R2 = 0.6683
Time (hours)
M
t
-
M
o
40 30 20 10
First order
R2 = 0.7635
−
l
o
g
 
(
M
t
-
M
o
)
0.0
0.1
0.2
0.3
0.4
0.5
B
0
Time (hours)
40 30 20 10
t
/
q
t
0.0
0.1
0.2
0.3
0.4
0.5
0.6
C
Pseudo-second order
R2 = 0.9985
Time (hours)
40 30 20 10 0
0
4
8
12
16
20 D
Parabolic diffusion
(
1
-
M
t
/
M
o
)
/
t
R2 = 0.7997
0
t−0.5 (hours)
20 15 10 5
0
15
30
45
60
75
90
0
E
Zero order
R2 = 0.3963
Time (hours)
M
t
−
M
o
40 30 20 10
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
First order
R2 = 0.7381
−
l
o
g
 
(
M
t
/
M
o
)
F
0
Time (hours)
40 30 20 10
0.0
0.1
0.2
0.3
0.4
t
/
q
t
G
Pseudo-second order
R2 = 0.9996
Time (hours)
40 30 20 10 0
0
20
40
60
80
H
Parabolic diffusion
(
1
−
M
t
/
M
o
)
/
t
R2 = 0.5926
0
t−0.5 (hours)
20 15 10 5International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1381
Antiproliferative nanohybrid compound
60
80
100
%
 
v
i
a
b
i
l
i
t
y
Time (hours)
 DMSO
 EA
 EAN
 ZnO
0 0.5 1.0 3.0 6.0
Figure 10 The effect of eA, eAN, and ZnO on the viability of rat hepatocyte cells 
at the concentration of 25 µg/mL.
Abbreviations: eA, ellagic acid; eAN, ellagic acid nanohybrid; ZnO, zinc oxide.
completed within 26 and 18 minutes in Na2CO3 and Na3PO4, 
respectively. The release rate of EA from EAN is obviously 
lower than the free EA, indicating that the EAN is a potential 
controlled-release drug system. The release of EA from the 
nanohybrid is obviously dependent on the types of anion in 
aqueous solution for ion exchange. It is worth noting that the 
rapid release during the first 5 hours is followed by a more 
sustained release of the EA, and 44% and 85% of EA was 
released from ZLH by Na2CO3 and Na3PO4 aqueous solution, 
respectively. A slower release was observed from 5 to 38 hours. 
The amount of EA released from EAN into aqueous solutions 
containing Na3PO4 was found to be higher than the Na2CO3, 
as shown in Figure 8B. The amount of EA released from the 
aqueous   solution at 38 hours was 94% (Table 2 and Figure 8) 
for Na3PO4 compared with about 69% for Na2CO3. Because 
we know that the more negative charge of phosphate anion will 
give a higher affinity for ion exchange with the intercalated EA 
anion, more release of EA is expected, and this is parallel to 
the release profiles observed in Figure 8.
In order to obtain more information on the release behav-
ior of EA from EAN, zeroth-, first-, pseudo-second-order 
kinetics and parabolic diffusion, were chosen to investigate 
the release kinetics of EA from the   nanohybrid. The equa-
tions are given in Table 2. On the basis of the four models, 
the fitted results of EA release profiles are given in Figure 9 
and Table 2. It can be seen that the pseudo-second-order 
model can be better fitted to the data of the EA release 
behavior than the other models. Figures 9C and G show the 
plots of t/qt versus t for the release of EA into Na2CO3 and 
Na3PO4 solution, respectively. For the Na2CO3, the correla-
tion coefficient (R2) and k valves are 0.9985 and 0.0044, 
respectively, compared with 0.9996 and 0.0175, respectively 
for Na3PO4. The saturated release amount, correlation 
coefficient (R2) and rate constant for pseudo-second-order 
model are also given in Table 2. This study indicates that 
EAN synthesized in this work shows controlled-release 
properties.
In vitro bioassay
Figure 10 and Table 3 show the effect of free EA, EAN, and 
ZnO on the viability, using rat hepatocytes cells at various 
incubation times of 0, 0.5, 1, 3 and 6 hours and at a con-
centration of 25 µg/mL. As shown in Figure 10, EA has a 
mild cytotoxic effect on the viability of the hepatocyte cells, 
similar to ZnO. Interestingly, the EAN also has a mild effect 
on the hepatocyte cells similar to that of free EA.
A closer look at Table 3 shows no significant toxic effect 
of EAN on the rat hepatocytes cells up to 6 hours, which 
indicates that EAN can be further used in the study using 
cancer cell lines.
Conclusion
This study shows that EA can be intercalated into the interlayer 
of ZLH under nonaqueous environment by direct reaction with 
ZnO for the formation of organic–inorganic nanohybrid. The 
resulting nanohybrid was obtained using 0.025 M EA. The 
obtained nanohybrid shows a basal spacing of 10.4 Å, which 
confirms the successful intercalation of EA into the interlayer 
of ZLH. In addition, FTIR and elemental analyses (CHNS) 
studies supported the intercalation of EA into ZLH interlayers 
for the nanohybrid formation, EAN. It was also found that the 
Table 3 Viability of hepatocytes during incubation with eA and eAN
0 h 0.5 h 1.0 h 3.0 h 6.0 h
control (1% DMsO) 97.4 ± 1.0aw 96.8 ± 0.8aw 96.2 ± 1.4aw 94.3 ± 1.2aw 92.5 ± 1.6ax
25 µg/mL eA 98.2 ± 1.0aw 94.3 ± 1.3ax 92.5 ± 1.2bx 89.4 ± 2.4by 83.4 ± 2.5by
25 µg/mL eAN 97.3 ± 1.1aw 94.8 ± 0.8ax 90.5 ± 1.8by 85.3 ± 4.3bz 77.2 ± 5.7cz
25 µg/mL ZnO 96.7 ± 1.5aw 93.2 ± 1.0bx 88.5 ± 1.3cy 84.3 ± 5.7by 73.4 ± 6.2cz
Notes: N = 3. Values are mean ± SD. Means with different superscript (a–c) differs significantly (P , 0.05) by ANOVA and Duncan multiple post-test in the same column 
and (w–z) differs significantly in the same row.
Abbreviations: eA, ellagic acid; eAN, ellagic acid nanohybrid; ZnO, zinc oxide.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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BET surface area declined from 6.4 to 3.6 m2/g when ZnO is 
transformed to EAN. The high loading of EA molecules inside 
the interlayers of about 58.8% is useful for controlled-release 
purposes, and the controlled-release study showed the drug 
active, EA was released in a controlled manner. The EAN has 
a mild effect on the hepatocyte cells similar to its counterpart, 
free EA, which indicates that the EAN can be further used in 
the study on cancer cell lines.
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